SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001839882-22-021300
Filing Date
2022-09-23
Accepted
2022-09-23 17:06:36
Documents
14
Period of Report
2022-09-23
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT admp-8k_092322.htm   iXBRL 8-K 30396
2 OPINION OF LATHAM & WATKINS, LLP ex5-1.htm EX-5.1 17654
6 GRAPHIC admp_001.jpg GRAPHIC 6992
  Complete submission text file 0001839882-22-021300.txt   236689

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT admp-20220923.xsd EX-101.SCH 3266
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT admp-20220923_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT admp-20220923_pre.xml EX-101.PRE 22385
8 EXTRACTED XBRL INSTANCE DOCUMENT admp-8k_092322_htm.xml XML 3589
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36242 | Film No.: 221262941
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences